We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MDRNA’s RNAi-Based Compounds Demonstrate High Potency Against Multiple Targets in Preclinical Studies
News

MDRNA’s RNAi-Based Compounds Demonstrate High Potency Against Multiple Targets in Preclinical Studies

MDRNA’s RNAi-Based Compounds Demonstrate High Potency Against Multiple Targets in Preclinical Studies
News

MDRNA’s RNAi-Based Compounds Demonstrate High Potency Against Multiple Targets in Preclinical Studies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MDRNA’s RNAi-Based Compounds Demonstrate High Potency Against Multiple Targets in Preclinical Studies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MDRNA, Inc. has announced positive in vivo efficacy data showing that its proprietary UsiRNA constructs are highly potent and highly specific against ApoB and Factor VII message.

The data was presented by Michael V. Templin, Ph.D., Vice President, Discovery Research and Pharmaceutical Development of MDRNA, at the TIDES Oligonucleotide and Peptide® Technology and Product Development Conference in Las Vegas, Nevada.

"Data from recent in vivo studies using our UsiRNAs targeting ApoB message confirm that RNA interference is the mechanism of action by which knockdown occurs, giving us high confidence that our UsiRNAs work by a sequence-specific mechanism," stated Barry Polisky, Ph.D., Chief Scientific Officer of MDRNA.

"Data from the Factor VII studies indicate that a siRNA in our lead formulation achieved greater than 90% knockdown at 1 mg/kg with duration of effect of up to 28 days. This level of inhibition and duration of effect meets or exceeds published data for Factor VII."

Dr. Polisky added, "Data from rodent studies with our DiLA2 delivery system also continue to show encouraging results, with potency, specificity and duration of effect data now achieved for four independent liver targets, including ApoB, PCSK9, DGAT2 and Factor VII. The absence of histological changes in the liver with doses up to 9 mg/kg in rodents confirms that our DiLA2 liposomes are well tolerated."
Advertisement